Amgen recommends rejection of 'mini-tender' offer from TRC Capital Corporation
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadian investment company, to purchase up to 500,000 shares of Amgen's common stock beginning on Oct. 14, 2019.
Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
- Details
- Category: Bayer
Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The new hub is the seventh pillar of Bayer's global network of LifeHubs designed to accelerate the co-exploration and development of pioneering solutions to solve global challenges in health and nutrition.
Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts.
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Details
- Category: AstraZeneca
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review.
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
- Details
- Category: Novartis
Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease (GvHD). The study met its primary endpoint of superior overall response rate (ORR) at day 28 of treatment with Jakavi, compared with best available therapy (BAT)[1].
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
- Details
- Category: Sanofi
Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using intensified, continuous biologics production technology. The new facility features leading-edge technology that connects the production process with research and development, paving the way for improved commercialization of important new medicines for patients.
More Pharma News ...
- Abbott and Omada Health partner to offer integrated digital health and coaching experience for people with Type 2 diabetes
- Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
- Abbott and Abbott Fund launch 'Future Well Kids' program to help students shape healthier lives
- Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
- Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
- AstraZeneca divests rights for Losec to Cheplapharm
- Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman